Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

doi:10.1084/jem.177.6.1675

This Article

	Full Text (PDF, 649K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Moreira, A. L.
	Articles by Kaplan, G.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Moreira, A. L.
	Articles by Kaplan, G.


Social Bookmarking

	What's this?

ARTICLES

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

AL Moreira, EP Sampaio, A Zmuidzinas, P Frindt, KA Smith and G Kaplan
Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York, New York 10021.

We have examined the mechanism of thalidomide inhibition of lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF- alpha) production and found that the drug enhances the degradation of TNF-alpha mRNA. Thus, the half-life of the molecule was reduced from approximately 30 to approximately 17 min in the presence of 50 micrograms/ml of thalidomide. Inhibition of TNF-alpha production was selective, as other LPS-induced monocyte cytokines were unaffected. Pentoxifylline and dexamethasone, two other inhibitors of TNF-alpha production, are known to exert their effects by means of different mechanisms, suggesting that the three agents inhibit TNF-alpha synthesis at distinct points of the cytokine biosynthetic pathway. These observations provide an explanation for the synergistic effects of these drugs. The selective inhibition of TNF-alpha production makes thalidomide an ideal candidate for the treatment of inflammatory conditions where TNF-alpha-induced toxicities are observed and where immunity must remain intact.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Faria, S. C., Ng, C. S., Hess, K. R., Phongkitkarun, S., Szejnfeld, J., Daliani, D., Charnsangavej, C. (2007). CT Quantification of Effects of Thalidomide in Patients with Metastatic Renal Cell Carcinoma. Am. J. Roentgenol. 189: 378-385 [Abstract] [Full Text]
Ge, Y., Montano, I., Rustici, G., Freebern, W. J., Haggerty, C. M., Cui, W., Ponciano-Jackson, D., Chandramouli, G. V. R., Gardner, E. R., Figg, W. D., Abu-Asab, M., Tsokos, M., Jackson, S. H., Gardner, K. (2006). Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Blood 108: 4126-4135 [Abstract] [Full Text]
Ye, Q., Chen, B., Tong, Z., Nakamura, S., Sarria, R., Costabel, U., Guzman, J. (2006). Thalidomide reduces IL-18, IL-8 and TNF-{alpha} release from alveolar macrophages in interstitial lung disease. Eur Respir J 28: 824-831 [Abstract] [Full Text]
Yang, X.-X., Hu, Z.-P., Xu, A.-L., Duan, W., Zhu, Y.-Z., Huang, M., Sheu, F.-S., Zhang, Q., Bian, J.-S., Chan, E., Li, X., Wang, J.-C., Zhou, S.-F. (2006). A Mechanistic Study on Reduced Toxicity of Irinotecan by Coadministered Thalidomide, a Tumor Necrosis Factor-{alpha} Inhibitor. J. Pharmacol. Exp. Ther. 319: 82-104 [Abstract] [Full Text]
Tefferi, A., Cortes, J., Verstovsek, S., Mesa, R. A., Thomas, D., Lasho, T. L., Hogan, W. J., Litzow, M. R., Allred, J. B., Jones, D., Byrne, C., Zeldis, J. B., Ketterling, R. P., McClure, R. F., Giles, F., Kantarjian, H. M. (2006). Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 108: 1158-1164 [Abstract] [Full Text]
Tisdale, M. J. (2006). Clinical Anticachexia Treatments. Nutr Clin Pract 21: 168-174 [Abstract] [Full Text]
Kiaei, M., Petri, S., Kipiani, K., Gardian, G., Choi, D.-K., Chen, J., Calingasan, N. Y., Schafer, P., Muller, G. W., Stewart, C., Hensley, K., Beal, M. F. (2006). Thalidomide and Lenalidomide Extend Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis. J. Neurosci. 26: 2467-2473 [Abstract] [Full Text]
Lee, C. P., Patel, P. M., Selby, P. J., Hancock, B. W., Mak, I., Pyle, L., James, M. G., Beirne, D. A., Steeds, S., A'Hern, R., Gore, M. E., Eisen, T. (2006). Randomized Phase II Study Comparing Thalidomide With Medroxyprogesterone Acetate in Patients With Metastatic Renal Cell Carcinoma. JCO 24: 898-903 [Abstract] [Full Text]
Gordon, J.N., Green, S.R., Goggin, P.M. (2005). Cancer cachexia. QJM 98: 779-788 [Abstract] [Full Text]
Schwartz, J. D., Sung, M., Schwartz, M., Lehrer, D., Mandeli, J., Liebes, L., Goldenberg, A., Volm, M. (2005). Thalidomide in Advanced Hepatocellular Carcinoma with Optional Low-Dose Interferon-{alpha}2a upon Progression. The Oncologist 10: 718-727 [Abstract] [Full Text]
Hsu, C., Chen, C.-N., Chen, L.-T., Wu, C.-Y., Hsieh, F.-J., Cheng, A.-L. (2005). Effect of Thalidomide in Hepatocellular Carcinoma: Assessment with Power Doppler US and Analysis of Circulating Angiogenic Factors. Radiology 235: 509-516 [Abstract] [Full Text]
Ferrante, J. V., Ferrante, A. (2005). Cutting Edge: Novel Role of Lipoxygenases in the Inflammatory Response: Promotion of TNF mRNA Decay by 15-Hydroperoxyeicosatetraenoic Acid in a Monocytic Cell Line. J. Immunol. 174: 3169-3172 [Abstract] [Full Text]
List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., Zeldis, J. B. (2005). Efficacy of Lenalidomide in Myelodysplastic Syndromes. NEJM 352: 549-557 [Abstract] [Full Text]
Amato, R. J. (2005). Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 16: 7-15 [Abstract] [Full Text]
Schey, S.A., Fields, P., Bartlett, J.B., Clarke, I.A., Ashan, G., Knight, R.D., Streetly, M., Dalgleish, A.G. (2004). Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma. JCO 22: 3269-3276 [Abstract] [Full Text]
Eleutherakis-Papaiakovou, V., Bamias, A., Dimopoulos, M. A. (2004). Thalidomide in cancer medicine. Ann Oncol 15: 1151-1160 [Abstract] [Full Text]
Kumar, S., Witzig, T. E., Rajkumar, S. V. (2004). Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies. JCO 22: 2477-2488 [Abstract] [Full Text]
Park, S.-J., Kim, H.-S., Yang, H.-M., Park, K.-W., Youn, S.-W., Jeon, S.-I., Kim, D.-H., Koo, B.-K., Chae, I.-H., Choi, D.-J., Oh, B.-H., Lee, M.-M., Park, Y.-B. (2004). Thalidomide as a Potent Inhibitor of Neointimal Hyperplasia After Balloon Injury in Rat Carotid Artery. Arterioscler. Thromb. Vasc. Bio. 24: 885-891 [Abstract] [Full Text]
Sayarlioglu, M., Kotan, M. C., Topcu, N., Bayram, I., Arslanturk, H., Gul, A. (2004). Treatment of Recurrent Perforating Intestinal Ulcers with Thalidomide in Behcet's Disease. The Annals of Pharmacotherapy 38: 808-811 [Abstract] [Full Text]
Gockel, H. R., Lugering, A., Heidemann, J., Schmidt, M., Domschke, W., Kucharzik, T., Lugering, N. (2004). Thalidomide Induces Apoptosis in Human Monocytes by Using a Cytochrome c-Dependent Pathway. J. Immunol. 172: 5103-5109 [Abstract] [Full Text]
Sparano, J. A., Gray, R., Giantonio, B., O'Dwyer, P., Comis, R. L. (2004). Evaluating Antiangiogenesis Agents in the Clinic: The Eastern Cooperative Oncology Group Portfolio of Clinical Trials. Clin. Cancer Res. 10: 1206-1211 [Abstract] [Full Text]
Gee, M. S., Makonnen, S., al-Kofahi, K., Roysam, B., Payvandi, F., Man, H.-W., Muller, G. W., Lee, W. M. F. (2003). Selective Cytokine Inhibitory Drugs with Enhanced Antiangiogenic Activity Control Tumor Growth through Vascular Inhibition. Cancer Res. 63: 8073-8078 [Abstract] [Full Text]
Robinson, N. D., Guitart, J. (2003). Recalcitrant, Recurrent Aphthous Stomatitis Treated With Etanercept. Arch Dermatol 139: 1259-1262 [Full Text]
Nasca, M. R, Micali, G., Cheigh, N. H, West, L. E, West, D. P (2003). Dermatologic and Nondermatologic Uses of Thalidomide. The Annals of Pharmacotherapy 37: 1307-1320 [Abstract] [Full Text]
Giamarellos-Bourboulis, E. J., Poulaki, H., Kostomitsopoulos, N., Dontas, I., Perrea, D., Karayannacos, P. E., Giamarellou, H. (2003). Effective Immunomodulatory Treatment of Escherichia coli Experimental Sepsis with Thalidomide. Antimicrob. Agents Chemother. 47: 2445-2449 [Abstract] [Full Text]
Ng, S. S. W., Gutschow, M., Weiss, M., Hauschildt, S., Teubert, U., Hecker, T. K., Luzzio, F. A., Kruger, E. A., Eger, K., Figg, W. D. (2003). Antiangiogenic Activity of N-substituted and Tetrafluorinated Thalidomide Analogues. Cancer Res. 63: 3189-3194 [Abstract] [Full Text]
Mesa, R. A., Steensma, D. P., Pardanani, A., Li, C.-Y., Elliott, M., Kaufmann, S. H., Wiseman, G., Gray, L. A., Schroeder, G., Reeder, T., Zeldis, J. B., Tefferi, A. (2003). A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 101: 2534-2541 [Abstract] [Full Text]
Mufti, G., List, A. F., Gore, S. D., Ho, A. Y.L. (2003). Myelodysplastic Syndrome. ASH Education Book 2003: 176-199 [Abstract] [Full Text]
Xu, Y., Villalona-Calero, M. A. (2002). Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13: 1841-1851 [Abstract] [Full Text]
Mohty, M., Stoppa, A.-M., Blaise, D., Isnardon, D., Gastaut, J.-A., Olive, D., Gaugler, B. (2002). Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide. J. Leukoc. Biol. 72: 939-945 [Abstract] [Full Text]
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., Kyle, R. A., Witzig, T. E. (2002). Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma. JCO 20: 4319-4323 [Abstract] [Full Text]
Curley, M. J., Hussein, S. A., Hassoun, P. M. (2002). Disseminated Herpes Simplex Virus and Varicella Zoster Virus Coinfection in a Patient Taking Thalidomide for Relapsed Multiple Myeloma. J. Clin. Microbiol. 40: 2302-2304 [Abstract] [Full Text]
van Deventer, S J H (2002). Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut 50: iii47-53 [Abstract] [Full Text]
Hussein, M. A. (2002). Nontraditional Cytotoxic Therapies for Relapsed/Refractory Multiple Myeloma. The Oncologist 7: 20-29 [Abstract] [Full Text]
Majumdar, S., Lamothe, B., Aggarwal, B. B. (2002). Thalidomide Suppresses NF-{kappa}B Activation Induced by TNF and H2O2, But Not That Activated by Ceramide, Lipopolysaccharides, or Phorbol Ester. J. Immunol. 168: 2644-2651 [Abstract] [Full Text]
Steins, M. B., Padro, T., Bieker, R., Ruiz, S., Kropff, M., Kienast, J., Kessler, T., Buechner, T., Berdel, W. E., Mesters, R. M. (2002). Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 99: 834-839 [Abstract] [Full Text]
Fujita, J., Mestre, J. R., Zeldis, J. B., Subbaramaiah, K., Dannenberg, A. J. (2001). Thalidomide and Its Analogues Inhibit Lipopolysaccharide-mediated Induction of Cyclooxygenase-2. Clin. Cancer Res. 7: 3349-3355 [Abstract] [Full Text]
Drenth, J. P. H., Vonk, A. G., Simon, A., Powell, R., van der Meer, J. W. M. (2001). Limited Efficacy of Thalidomide in the Treatment of Febrile Attacks of the Hyper-IgD and Periodic Fever Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. J. Pharmacol. Exp. Ther. 298: 1221-1226 [Abstract] [Full Text]
Vincent Rajkumar, S., Kyle, R. A. (2001). Thalidomide in the Treatment of Plasma Cell Malignancies. JCO 19: 3593-3595 [Full Text]
Raza, A., Meyer, P., Dutt, D., Zorat, F., Lisak, L., Nascimben, F., du Randt, M., Kaspar, C., Goldberg, C., Loew, J., Dar, S., Gezer, S., Venugopal, P., Zeldis, J. (2001). Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98: 958-965 [Abstract] [Full Text]
Rook, G.A.W., Seah, G., Ustianowski, A. (2001). M. tuberculosis: immunology and vaccination. Eur Respir J 17: 537-557 [Abstract] [Full Text]
Karim, M Y, Ruiz-Irastorza, G, Khamashta, M A, Hughes, G R. (2001). Update on therapy -- thalidomide in the treatment of lupus. Lupus 10: 188-192 [Abstract]
Teo, S. K., Evans, M. G., Brockman, M. J., Ehrhart, J., Morgan, J. M., Stirling, D. I., Thomas, S. D. (2001). Safety Profile of Thalidomide after 53 Weeks of Oral Administration in Beagle Dogs. Toxicol Sci 59: 160-168 [Abstract] [Full Text]
Badley, A. D., Pilon, A. A., Landay, A., Lynch, D. H. (2000). Mechanisms of HIV-associated lymphocyte apoptosis. Blood 96: 2951-2964 [Abstract] [Full Text]
Schoeman, J. F., Springer, P., Ravenscroft, A., Donald, P. R., Bekker, L.-G., van Rensburg, A. J., Hanekom, W. A., Haslett, P. A. J., Kaplan, G. (2000). Adjunctive Thalidomide Therapy of Childhood Tuberculous Meningitis: Possible Anti-Inflammatory Role. J Child Neurol 15: 497-503 [Abstract]
Baidas, S. M., Winer, E. P., Fleming, G. F., Harris, L., Pluda, J. M., Crawford, J. G., Yamauchi, H., Isaacs, C., Hanfelt, J., Tefft, M., Flockhart, D., Johnson, M. D., Hawkins, M. J., Lippman, M. E., Hayes, D. F. (2000). Phase II Evaluation of Thalidomide in Patients With Metastatic Breast Cancer. JCO 18: 2710-2717 [Abstract] [Full Text]
Brooks, S. A., Rigby, W. F. C. (2000). Characterization of the mRNA ligands bound by the RNA binding protein hnRNP A2 utilizing a novel in vivo technique. Nucleic Acids Res 28: e49-e49 [Abstract] [Full Text]
Davey, P.P., Ashrafian, H. (2000). New therapies for heart failure: is thalidomide the answer?. QJM 93: 305-311 [Abstract] [Full Text]
Dios, P. D., Sopena, B., Cameselle, J., Butron, M., Crespo, M., Ocampo, A. (2000). Thalidomide for the Treatment of Acquired Immunodeficiency Syndrome-Associated Refractory Oral Ulcers. Arch Otolaryngol Head Neck Surg 126: 89-92 [Abstract] [Full Text]
Kapelushnik, J., Weiss, L., Pappo, O., Okon, E., Or, R. (1999). Thalidomide does not interfere with graft-versus-leukemia reactivity in mice. J Oncol Pharm Pract 5: 179-183 [Abstract]
Young, J. B. (1999). Angiotensin-converting enzyme inhibitors and cytokines in heart failure: dose and effect?. J Am Coll Cardiol 34: 2068-2071 [Full Text]
Gozzi, P., Påhlman, I., Palmér, L., Grönberg, A., Persson, a. S. (1999). Pharmacokinetic-Pharmacodynamic Modeling of the Immunomodulating Agent Susalimod and Experimentally Induced Tumor Necrosis Factor-alpha Levels in the Mouse. J. Pharmacol. Exp. Ther. 291: 199-203 [Abstract] [Full Text]
Yeh, S.-S., Schuster, M. W (1999). Geriatric cachexia: the role of cytokines. Am. J. Clin. Nutr. 70: 183-197 [Abstract] [Full Text]
Schuld, A., Mullington, J., Hermann, D., Hinze-Selch, D., Fenzel, T., Holsboer, F., Pollmacher, T. (1999). Effects of granulocyte colony-stimulating factor on night sleep in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 276: R1149-R1155 [Abstract] [Full Text]
Hermann, G. E., Tovar, C. A., Rogers, R. C. (1999). Induction of endogenous tumor necrosis factor-alpha : suppression of centrally stimulated gastric motility. Am. J. Physiol. Regul. Integr. Comp. Physiol. 276: R59-R68 [Abstract] [Full Text]
Marriott, J. B., Westby, M., Cookson, S., Guckian, M., Goodbourn, S., Muller, G., Shire, M. G., Stirling, D., Dalgleish, A. G. (1998). CC-3052: A Water-Soluble Analog of Thalidomide and Potent Inhibitor of Activation-Induced TNF-{alpha} Production. J. Immunol. 161: 4236-4243 [Abstract] [Full Text]
Rocha, M. F.�G., Soares, A. M., Flores, C. A., Steiner, T. S., Lyerly, D. M., Guerrant, R. L., Ribeiro, R. A., Lima, A. A.�M. (1998). Intestinal Secretory Factor Released by Macrophages Stimulated with Clostridium difficile Toxin A: Role of Interleukin 1beta. Infect. Immun. 66: 4910-4916 [Abstract] [Full Text]
Bala, S., Hastings, K. L., Kazempour, K., Inglis, S., Dempsey, W. L. (1998). Inhibition of Tumor Necrosis Factor Alpha Alters Resistance to Mycobacterium avium Complex Infection in Mice. Antimicrob. Agents Chemother. 42: 2336-2341 [Abstract] [Full Text]
Lührmann, A., Thölke, J., Behn, I., Schumann, J., Tiegs, G., Hauschildt, S. (1998). Immunomodulating Properties of the Antibiotic Novobiocin in Human Monocytes. Antimicrob. Agents Chemother. 42: 1911-1916 [Abstract] [Full Text]
Porro, G., Bertolini, G., Bonardi, M. A., Giovanetti, E., Lento, P., Leoni, F., Modena, D., Pavich, G., Marcucci, F. (1998). Diaminic Carbonates, a New Class of Anti-inflammatory Compounds: Their Biological Characterization and Mode of Action. J. Pharmacol. Exp. Ther. 285: 193-200 [Abstract] [Full Text]
Krown, S. E. (1998). Clinical Overview: Issues in Kaposi's Sarcoma Therapeutics. J Natl Cancer Inst Monogr 1998: 59-63 [Abstract] [Full Text]